Cheryl Schwartz Joins EMD Serono as Head of U.S. Fertility and Endocrinology

Rockland, Massachusetts, July 31, 2018 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, today announced that Cheryl Schwartz joined the company as Senior Vice President and Head of U.S. Fertility and Endocrinology. In this role, Ms. Schwartz will oversee the strategic direction of EMD Serono’s Fertility, Fertility Technologies and Endocrinology businesses in the U.S.

“EMD Serono has long been a leader in the Fertility and Endocrinology spaces, showing unwavering commitment to these communities for more than 20 years by offering medications, devices, technologies and services,” said Gary Zieziula, President and Managing Director of EMD Serono. “We are thrilled to welcome Cheryl, a seasoned healthcare executive with a proven track record of success whose experience aligns with our own commitment to meeting the needs of patients.”

Prior to joining EMD Serono, Ms. Schwartz held positions of increasing responsibility at Pfizer Inc., where she most recently served as General Manager of the U.S. Biosimilars business. In this role, she led Pfizer’s efforts to successfully commercialize a broad portfolio of assets for the emerging US Biosimilars market. Previously, Ms. Schwartz also served as Vice President and Global Commercial Lead in Pfizer Vaccines supporting Prevnar 13®, and a range of other U.S. and Global commercial leadership roles spanning product lifecycles and therapeutic areas. Prior to joining Pfizer, Ms. Schwartz’s health care industry experience included roles at Forest Laboratories and Oxford Health Plans.

Ms. Schwartz holds an MBA from the Kellogg School of Management at Northwestern University and a bachelor’s degree from the University of Michigan-Ann Arbor. 

Prevnar 13 is a registered trademark of Wyeth LLC

About EMD Serono, Inc. 
EMD Serono - the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada – is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases. The business is committed to transforming lives by developing and delivering meaningful solutions that help address the therapeutic and support needs of individual patients. Building on a proven legacy and deep expertise in neurology, fertility and endocrinology, EMD Serono is developing potential new oncology and immuno-oncology medicines while continuing to explore potential therapeutic options for diseases such as psoriasis, lupus and multiple sclerosis. Today, the business has approximately 1,300 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts. www.emdserono.com

About Merck KGaA, Darmstadt, Germany 
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.

Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.